Inovio Pharmaceuticals Inc (INO)

[ppnlf]

It's a pity that the interview only repeats much of what is in the public domain, which I guess is what Dr Kim must do. (Certainly from the perspective of an INO long always looking for news!)

What I had not been aware of until this interview was the institutional investment: Cambrian and First Eagle. Does anyone know what percentage is now held by institutions?

I would appreciate it if someone could point me to where is explained Inovio's competitive advantages in terms of DNA vaccine development (including SynCon). I find the message confused between Inovio's strengths in design and delivery (electroporation).